News
-
-
-
-
PRESS RELEASE
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities -
-
-
-
PRESS RELEASE
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides, Inc. commences evaluation of clinical drug NV-387 for Measles virus treatment, utilizing innovative nanomedicine technology. Company aims to combat Measles outbreak and provide effective antiviral solution -
-
PRESS RELEASE
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
NanoViricides, Inc. declares its business is not affected by US tariff policies or spending cuts, focusing on developing broad-spectrum antiviral drugs. The company's NV-387 shows potential for treating measles
